193 results about "Monkeypox virus" patented technology

The invention discloses a primer combination for detecting monkey pox viruses and identifying monkey pox viruses Ia, Ib and II, and belongs to the technical field of molecular biology, the nucleotide sequences of specific primers and probes are shown as SEQ ID NO.1-SEQ ID NO.12, and the primer combination aims at solving the problem that in the prior art, new evolutionary branch Ib types of monkey pox viruses cannot be accurately typed, and the detection sensitivity is high. According to the present invention, the defects that the monkey pox virus and the orthopox virus have the cross reaction are overcome, the genome difference of different evolutionary branches is analyzed through the bioinformatics system, the primer probe composition capable of simultaneously detecting the monkey pox virus and carrying out accurate typing is analyzed and screened, and the primer combination can detect 200 copies / mL of the monkey pox virus with high specificity and high sensitivity. Meanwhile, detection of the monkey pox virus and identification of the types Ia, Ib and II of the monkey pox virus are realized in a reaction system, so that different monkey pox branches can be distinguished, and treatment and prevention can be performed in a more targeted manner.

The invention belongs to the technical field of immunotherapy, and particularly relates to a monkey pox virus antigen epitope peptide and application thereof. The invention aims to solve the technical problem that at present, a T cell antigen epitope peptide for universal vaccines of monkey pox viruses is not developed in the field of monkey pox viruses. According to the technical scheme of the invention, the amino acid sequence of the monkey pox virus antigen epitope peptide is shown as SEQ ID No.2. The antigen epitope peptide provided by the invention has very strong immunogenicity, and can induce antigen-specific CD8 + T cells; the antibody can be directly loaded to antigen presenting cells, can activate T cells and effectively induce T cell immunity, and can be used for research and development and preparation of universal vaccines for monkey pox viruses, research and development of drugs and clinical treatment.

The invention discloses an anti-monkey pox virus antibody as well as a preparation method and application thereof. The invention specifically discloses eight kinds of antibodies (A35R-9E4, A35R-9F8, A35R-10C4, A35R-10D5, A35R-10E7, A35R-10H6, A35R-18E2 and A35R-18H2) which have very good affinity to monkey pox virus A35R protein, and the eight kinds of antibodies have very good neutralizing activity and a certain in-vivo protection effect.

The invention discloses a monoclonal antibody for resisting monkey pox virus M1R protein and application of the monoclonal antibody. The invention specifically discloses a plurality of antibodies (M1R-12E10, M1R-12H5, M1R-12H6, M1R-24A7 and M1R-24H1) which have very good specificity and affinity to an M1R protein, and the antibodies have very good neutralizing activity and a certain in-vivo protection effect.

The invention provides an ultra-sensitive and high-specificity primer pair and crRNA for instantly detecting monkey pox virus, a kit and application thereof, and belongs to the technical field of molecular biological detection. The primer pair and the crRNA disclosed by the invention comprise a front primer, a rear primer and the crRNA. According to the primer pair and the crRNA disclosed by the invention, immediate detection of the MIRRA-CRISPR-Cas13a mediated monkey pox virus can be realized, the detection sensitivity is high, the specificity is strong, and rapid, accurate and sensitive identification of the monkey pox virus can be realized. Through implementation, experiments show that the detection limit of the primer pair and the crRNA for detecting the monkey pox virus can reach 14.4 copies / mL, and the primer pair and the crRNA have important significance on accurate clinical diagnosis of the monkey pox virus and epidemiological investigation.

The invention discloses a monkey pox virus epitope mRNA composition and application thereof, and relates to the technical field of biological medicines. The monkey pox virus epitope mRNA composition comprises mRNA encoding an epitope or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with the epitope and having the same immunogenicity. The vaccine can generate a high-level immune protection effect aiming at the monkey pox virus, can be used for preparing a medicine for preventing and treating the monkey pox virus, and has a wide application prospect clinically.

The invention provides an immunochromatographic test strip for quantitatively detecting monkey pox virus based on fluorescent latex microspheres, which takes europium chelate Eu (DBM) 3Phen-loaded monodisperse carboxylated polystyrene copolymer microspheres as a signal substance, and the microspheres are subjected to acid-base treatment before loading to loosen the surface structure of the microspheres so as to improve the loading capacity; the surface compound of the test strip is prepared by coupling carboxyl on the surface of the microsphere with an antibody. The invention also discloses a preparation method of the test strip. The kit is convenient for rapidly and accurately detecting the monkey pox virus, and has the characteristics of simplicity, rapidness, no toxicity and low cost.

The application relates to an antibody against monkeypox virus and a preparation method thereof, and the humanized monkeypox virus antibody H3-14A7 is obtained by screening memory B cells of a human antibody against H3 specific binding mouse. The H3-14A7 has the characteristics of strong monkeypox virus binding capacity, good in-vitro neutralization, large affinity and in-vivo protection.

The invention relates to the technical field of medicines, in particular to application of salinomycin in preparation of oral medicines for preventing or treating monkey pox virus (MPXV) infection. Salinomycin is a polyether antibiotic produced by actinomycetes. It is found for the first time that salinomycin can efficiently inhibit monkey pox virus infection on the cell culture level, and can significantly improve the survival rate of mice infected with monkey pox virus in small animal living bodies. More importantly, salinomycin can be administered by oral administration, has good bioavailability and safety, and provides a brand new treatment means for monkey pox virus infection. The medicinal value of salinomycin in resistance to monkey pox virus infection is reported for the first time at home and abroad, and the application prospect of salinomycin in the field of viral disease treatment is expanded.

The invention relates to a monkey pox virus nano vaccine based on an STING agonist and silicon nanoparticles as well as a preparation method and application of the monkey pox virus nano vaccine. The nano vaccine comprises a monkey pox virus antigen, the silicon nanoparticles and the STING agonist, the monkey pox virus antigen is combined to the surface of the silicon nanoparticle through a DogTag-DogCatcher system; the STING agonist is connected to the surface of the monkey pox virus antigen. The monkey pox virus antigen is covalently coupled with the silicon nanoparticles, and the antigen is displayed on the surfaces of the particles in a specific spatial orientation manner, so that the multivalence and accessibility of the antigen are enhanced, the shielding effect of the silicon nanoparticles on epitopes of the antigen is reduced, and the immune response induced by the vaccine is higher than that of a monomer immunogen protein.

The invention provides a novel vaccine based on an adenovirus vector and application thereof. According to the present invention, the suitable monkey pox virus gene is selected for the first time, and is efficiently integrated with the chimpanzee virus vector (AdC68) to prepare the ideal virus vaccine, and the ideal virus vaccine is suitable for nasal cavity immunization and muscle immunization, and has good nasal cavity immunization effect. The novel monkey pox vaccine can be effectively used for prevention and control of monkey pox virus and vaccinia virus infection, and the two types of viruses are considered.

The invention discloses an application of Arcyriaflavin A or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating monkey pox virus infection. The invention finds that the Arcyriaflavin A can obviously inhibit the replication of the monkey pox virus in a Vero cell, and the IC50 of the Arcyriaflavin A for inhibiting the Ib branch monkey pox virus and the IC50 of the Arcyriaflavin A for inhibiting the IIb branch monkey pox virus are 0.66 mu M and 0.96 mu M respectively. The invention also verifies that the Arcyriaflavin A has extremely low toxicity to Vero cells, and the toxicity CC50 of the Arcyriaflavin A to the cells is 41.51 mu M when the Arcyriaflavin A is used for inhibiting the proliferation of the monkey pox virus, so that the Arcyriaflavin A can be used for effectively inhibiting the replication of the monkey pox virus within the safe use range of the Arcyriaflavin A. The invention provides a new choice for the prevention and treatment of monkey pox, and has important significance for the prevention and treatment of monkey pox.

The present invention relates to a recombinant chimeric antigen targeting poxvirus (particularly monkeypox virus), a subunit vaccine thereof, and its application. The recombinant chimeric antigen of the present invention comprises two immunogens arranged in a specific manner: monkeypox virus A35 protein or its antigenic fragment (or its derivative peptide segment) and monkeypox virus M1 protein or its antigenic fragment (or its derivative peptide segment), which can stimulate immune responses against two infectious virus particles: intracellular mature virus particles (IMV) and extracellular enveloped virus particles (EEV), thereby efficiently stimulating specific immune protection against monkeypox virus. In addition, the poxvirus vaccine of the present invention also has good safety, rapid responsiveness and production capacity support, and has excellent clinical application prospects.

The invention discloses a method for detecting high sensitivity of monkey pox virus by a one-pot method RPA-CRISPR based on temperature control, and the method comprises the following steps: establishing a temperature-controlled RPA and CRISPR-Cas12b combined detection method, which is called as CRATS for short, by utilizing the reaction temperature difference between RPA amplification and CRISPR-Cas12b cutting; the reaction process in a tube system is regulated and controlled by stages through a temperature switching strategy: target amplification is completed at 37 DEG C firstly, then the temperature is raised to 60 DEG C, Cas12b cutting is started, so that sequential separation of amplification and cutting reactions is realized, and finally detection is realized through a fluorescence signal released by molecular beacon breakage. The problem that Cas enzyme cutting activity interferes with the amplification process in a traditional one-pot method reaction is solved, the detection sensitivity and specificity are improved, and a new technical means is provided for on-site rapid detection of the monkey pox virus.

The present invention relates to specific monoclonal antibodies and their applications. The amino acid sequence of the light chain CDR1 of the monoclonal antibody is shown in SEQ ID No. 1, the amino acid sequence of CDR2 is shown in SEQ ID No. 2, and the amino acid sequence of CDR3 is shown in SEQ ID No. 3; the amino acid sequence of the heavy chain CDR1 of the monoclonal antibody is shown in SEQ ID No. 4, the amino acid sequence of CDR2 is shown in SEQ ID No. 5, and the amino acid sequence of CDR3 is shown in SEQ ID No. 6. The present invention uses recombinant monkeypox virus surface protein E8L as an antigen. The screened monoclonal antibodies have good affinity for the recombinant monkeypox virus surface protein E8L at the molecular and cellular levels, can significantly inhibit the infection efficiency of VACV replication-deficient strains in VERO cells, and have good in vitro neutralization effect against monkeypox virus.

This invention relates to monoclonal antibodies for detecting A35R protein and their applications. This invention screened six antibodies, including antibody 4E7, antibody 11G12, antibody 6F10, antibody 6C11, antibody 18C3, and antibody 23A7. Specifically, this invention discloses the amino acid sequences of the heavy chain variable region and the light chain variable region of the above antibodies, as well as the amino acid sequences of their complementarity-determining regions and framework regions. Antibodies 4E7 and 11G12 can bind not only to the A35R-MPXV protein but also to its homologs A35R-CPXV, A35R-VTT8, and A35R-Variola. Antibodies 6F10, 6C11, 23A7, and 18C3 can specifically recognize the A35R-MPXV protein. The monoclonal antibodies described above all exhibit high binding capacity to the A35R protein, making them suitable for the sensitive and specific detection and prevention of monkeypox virus A35R protein. They can also be used clinically for the diagnosis and treatment of monkeypox virus infection-related diseases.

Provided herein are methods of producing immunoglobulin Y (IgY) antibodies against monkeypox virus. The method includes immunizing hens with a peptide encoding at least one immunogenic domain of A29 fusion protein from the monkeypox virus and isolating the IgY antibodies against the A29 fusion protein from yolks of eggs laid by the immunized hens. Pharmaceutical compositions containing the IgY antibodies and methods of inhibiting or treating monkeypox virus infection are also provided.

This application discloses antibodies against monkeypox virus, their preparation methods, and applications. Specifically, this application discloses eight antibodies (A35R-9E4, A35R-9F8, A35R-10C4, A35R-10D5, A35R-10E7, A35R-10H6, A35R-18E2, and A35R-18H2) that have excellent affinity for the monkeypox virus A35R protein, and that they exhibit good neutralizing activity and certain in vivo protective effects.

The present invention provides a monovalent multi-antigen vaccine against monkeypox virus and its application. Specifically, the present invention provides a monovalent multi-antigen fusion protein against monkeypox virus, and the fusion protein has a first fusion protein element containing A35R and M1R proteins and a second fusion protein element containing A29L and B6R proteins from the N-terminus to the C-terminus. In the present invention, A35R, M1R, A29L, and B6R are rationally combined as antigen components into a single protein molecule to prepare a monovalent mRNA vaccine. The experimental results show that the mRNA vaccine of the present invention can ensure the efficient expression of the target protein in vivo and can induce a high level of neutralizing antibodies.

The invention discloses a novel one-pot RPA-CRISPR method for detecting monkey pox virus based on a sucrose-assisted multiphase solution system, sucrose is added in RPA reaction to increase the density of the RPA reaction, the RPA reaction is placed at the bottom of a tube, and the CRISPR reaction with lower density is kept in a water phase and located at the top of the RPA reaction; in a one-tube reaction process, newly accumulated RPA amplicons trigger non-specific cutting of Cas12a for ssDNA-FQ, so that a fluorophore is released, a real-time fluorescence signal is detected by using a fluorescence detector, and end point fluorescence can be visualized under a blue light source; compared with the prior art, the one-pot RPA-CRISPR method of the multiphase solution system is constructed by using the sucrose to increase the RPA reaction density, rapid, convenient and reliable detection of the monkey pox virus is realized, prevention and control of the monkey pox epidemic situation are facilitated, and a good example is provided for actual field detection application of the sucrose-assisted multiphase solution system.

The invention relates to the technical field of medicines, in particular to application of aspiramycin and / or imiquimod in preparation of a medicine for treating VACV. Aspiramycin and imiquimod which are screened from medicines on the market have antiviral activity, and experimental data show that the Aspiramycin and the imiquimod have anti-VACV medicine activity. Aspiramycin and imiquimod (especially combined application) are used for preparing the medicine for treating VACV, so that the time and cost of preclinical research can be greatly reduced. As the action mechanism of the pox viruses is not unique to the VACV, the combined strategy has the potential to be expanded to infection treatment of other pox viruses (such as monkey pox virus MPXV) and even other DNA (Deoxyribose Nucleic Acid) viruses.

The present invention belongs to the field of biopharmaceutical technology, and specifically relates to a monoclonal antibody that binds to the monkeypox virus B6R protein and its application. The antibody is a combination of any one or more of B6R-B5, B6R-F6, and B6R-F11, and the B6R-B5, B6R-F6, and B6R-F11 all contain a heavy chain variable region and a light chain variable region, the heavy chain variable region having three heavy chain CDRs, and the light chain variable region having three light chain CDRs. The present invention provides three groups of monoclonal antibodies with excellent affinity for monkeypox virus B6R and disclosed sequences of each heavy chain and light chain variable region, providing technical support for the preparation of monkeypox virus detection and diagnostic reagents, and is expected to be developed into a specialized product for screening and diagnosis of monkeypox virus, with high application value for the prevention, control, and treatment of monkeypox virus.

The application belongs to the technical field of image recognition, and discloses a monkeypox virus classification method and system based on image comparison and a storage medium, which comprises an individual reference modeling module, collects normal skin and initial lesion images of a healthy side of a patient, generates a healthy texture template and an initial lesion reference library, performs gray scale normalization on the healthy texture template and the initial lesion reference library through adaptive histogram stretching, and outputs a comparison reference image group; a symptom density quantification module, acquires a current monitoring image of the patient, segments a lesion area in combination with the comparison reference image group, extracts layered features of the lesion area to generate a three-dimensional symptom density vector, extracts texture roughness of a surface of the lesion area, and constitutes a lesion quantification data set; the accuracy of disease monitoring is improved, and a clinical nursing process is optimized.

The present invention provides the use of a reagent capable of specifically binding to at least one state of monkeypox virus in EEV and IEV in a subject sample in the preparation of a kit for early screening of monkeypox virus infection. Further, the subject refers to an individual without obvious epidermal symptoms. The reagent provided by the present invention that can bind to at least one state of monkeypox virus has higher accuracy and sensitivity when applied to the preparation of a kit for early screening of monkeypox virus infection.

The present application relates to a kind of artificially synthesized recombinant monoclonal antibody with human antibody amino acid sequence as framework.The present application uses phage display technology, and obtains one monoclonal antibody H11 from Tomlinson I+J phage library, and these new amino acid sequences constitute CDR1, CDR2 and CDR3 region, can be combined with A29L protein specific binding.It shows good stability, high specificity and high affinity and other characteristics, provide tool support for subsequent monkeypox virus diagnosis and detection with A29L protein as target.

The invention relates to the field of antibody engineering, in particular to a monoclonal antibody specifically targeting a monkey pox virus and application of the monoclonal antibody. According to the invention, by screening mouse memory B cells specifically combined with monkey pox virus envelope protein A35R, monkey pox virus antibodies 1H4, 3H3, 3H6, 13H1 and 17H1 with high neutralization activity are obtained. Wherein 17H1 has excellent affinity and neutralizing efficacy on monkey pox virus and has a strong in-vivo protection effect, and 100% of survival rate of challenged mice is achieved in prevention and treatment experiments. The sequence of the antibody is completely different from that of an existing monkey pox virus antibody, and a new candidate product is provided for detection, diagnosis, prevention and treatment of the monkey pox virus.

The invention belongs to the technical field of biological detection, and particularly relates to a one-tube self-amplification system, kit and method for detecting monkey pox virus. The one-tube self-amplification system comprises a DF probe for detecting DNA of a monkey pox virus B6R gene and crRNA (Complementary Ribonucleic Acid); the nucleotide sequence of the DF probe is as shown in SEQ ID NO: 3, and the nucleotide sequence of the crRNA is as shown in SEQ ID NO: 4. The trans-cleavage activity of Cas12a and affinity difference between phi29 DNA polymerase and single-chain and double-chain states of a probe are utilized, so that the problem of substrate competition of two enzymes in a co-reaction system is effectively solved, and efficient synergy of a double-signal amplification system in the space-time dimension is realized. The monkey pox virus DNA ultrafast signal amplification can be achieved within 8 min, the lowest detection limit is 87.68 aM (52.8 copies / microliter), and by combining a virus nucleic acid thermal cracking method, sample entering and result obtaining can be achieved within 10 min.

Disclosed are an assay, method, and kit for detecting a monkeypox virus (MPXV) and the application thereof. The assay may be used alone or in combination with another assay or assays. The method of using and kit includes a composition used for detecting MPXV, wherein the composition is composed of a primer pair and a probe. The primer pair is composed of two single-stranded nucleic acid molecules shown in the first sequence and the second sequence in a sequence list, and the sequence of the probe is the third sequence in the sequence list. The kit is used for detecting MPXV, and has advantages of providing real-time screening of MPXV reducing cross-reaction to other pox diseases, and increasing specificity to MPXV for disease prevention and improvement of public health.

The present invention specifically relates to a monoclonal antibody 2D7, which is directed against the monkeypox virus A35R protein. The present invention first repeats and concatenates the MPXV A35S gene sequence via a linker (Gly4Ser)3, and then uses this as an immunogen to screen and obtain the monoclonal antibody 2D7, which is directed against the monkeypox virus A35R protein. The heavy chain of this monoclonal antibody comprises CDR1, CDR2, and CDR3 composed of the amino acid sequences shown in SEQ ID NOs. 1 to 3, and the light chain comprises CDR1, CDR2, and CDR3 composed of the amino acid sequences shown in SEQ ID NOs. 4 to 6. Further experimental studies have revealed that it has good specificity, high binding activity and affinity, and can be used in colloidal gold rapid detection kits, laying the foundation for the detection of monkeypox virus A35R protein.

The invention belongs to the technical field of biology, and discloses an anti-monkey pox virus E8 antibody or an antigen binding fragment thereof and application thereof. The invention provides an anti-monkey pox virus E8 monoclonal antibody 2F6, 9G4, 9H1 or 10E11, which can specifically recognize and target orthopox viruses such as monkey pox, vaccinia and the like, and shows efficient virus neutralizing capacity. The clinical application value of preventing and treating orthopoxvirus infection is realized; the compound can be used for detecting orthopoxvirus, diagnosing diseases related to orthopoxvirus infection and preventing and / or treating orthopoxvirus infection and / or diseases related to orthopoxvirus infection.